Akero raised to Buy at Bank of America after liver drug data
Bank of America upgraded Akero Therapeutics (NASDAQ:AKRO) on Thursday, citing what it called “game-changing” data the company disclosed from a mid-stage trial for its lead drug efruxifermin against the liver disorder metabolic dysfunction-associated steatohepatitis (MASH).
Akero drug reverses liver scarring in study of severe MASH patients
Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused by a disease known as MASH.
Akero Therapeutics Stock Doubles on Liver Data
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically intended to treat MASH.
Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the breakthrough Phase 2b SYMMETRY data.
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver fibrosis and safety.
Akero soars as drug shows it reverses scarring in liver disease patients
By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse scarring of the organ without worsening the condition in a keenly awaited mid-stage trial.
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results
Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.
STAT14h
MASH drugs reach a meaningful tipping point for patients and investors
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Akero's Efruxifermin Shows Cirrhosis Reversal In MASH Patients, Stock Soars In Pre-Market
In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated ...
The American Journal of Managed Care3d
Amplifying Impact: Efruxifermin Plus GLP-1RA Elevates MASH Outcomes
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Akero Therapeutics Shares Double After Positive Study Results for Efruxifermin
Akero Therapeutics shares doubled to $55.64 in premarket trading after the company said it saw positive preliminary topline results from its Phase 2b study evaluating the efficacy and safety of its ...
Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b cirrhosis trial
Akero Therapeutics (AKRO) released preliminary topline week 96 results from SYMMETRY, a Phase 2b study evaluating the efficacy and safety of ...
BioSpace3d
Akero Rebounds as Benefit Deepens in Key Mid-Stage MASH Trial
After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...
American Association of Individual Investors3d
Why Akero Therapeutics, Inc.’s (AKRO) Stock Is Up 97.52%
Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to ...
Akero Therapeutics’ Efruxifermin Shows Promise: Buy Rating Backed by Upcoming SYMMETRY Data and Potential Stock Upside
Analyst David Lebowitz of Citi maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $65.00.Invest ...